Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

HMNC Brain Health to Present Advances in Precision Psychiatry and Psychedelics at CNS Summit 2024 in Boston

MUNICH, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health (or “HMNC”), a clinical-stage precision psychiatry biopharma company, pioneering the development of personalized therapies powered by predictive companion diagnostics, today announced its participation at CNS Summit, the leading life sciences gathering, taking place from November 10-13, 2024, in Boston, Massachusetts. This year’s event brings together the leading minds in the life sciences, and HMNC Brain Health will play a pivotal role in two key discussions shaping the future of precision psychiatry and psychedelics.

Panel: Dr. Hans Eriksson, Chief Medical Officer at HMNC Brain Health, will join a panel to discuss the future of psychedelics in mental health care. The panel, “Psychedelic Forum Spotlight Session,” will be held on Tuesday, November 12, 2024, from 1:00 to 1:50 PM ET in session room Renoir 1/2. Alongside other industry leaders, Dr. Eriksson will delve into breakthrough innovations and the regulatory landscape that could transform the treatment for conditions such as depression and PTSD. Joining him on this panel are:

  • Kabir Nath, Co-CEO, Compass Pathways (Chair)
  • Srinivas Rao, Chief Scientific Officer, Atai Life Sciences
  • Dan Karlin, Chief Medical Officer, MindMed

This panel will address pressing questions about commercial viability, safety profiles, and next steps for psychedelics in mainstream treatment options, giving investors and industry insiders a glimpse into what’s next for this evolving field.

Poster Presentation: In a significant showcase of its precision psychiatry advancements, Dr. Daniel Gehrlach, Associate Director of Biomarkers at HMNC Brain Health, will present research that could redefine treatment pathways for mental health disorders. His poster, titled “Precision Psychiatry with Co-Development of Genetic Companion Diagnostics: A Novel Approach for Clinical Development,” will be presented on:

  • Date: Monday, November 11, 2024
  • Time: 5:00 to 7:00 PM ET
  • Poster Number: 28

Dr. Gehrlach’s presentation will unveil HMNC’s innovative use of genetic companion diagnostics to guide psychiatric treatments for individual patients, a step that promises to significantly increase efficacy and reduce trial-and-error in mental health therapies. This poster will highlight HMNC’s methods in developing personalized treatments for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Together, these presentations underscore HMNC Brain Health’s leadership at the intersection of neuroscience, precision medicine, and next-generation psychiatric treatments.

To schedule a one-on-one meeting with HMNC’s management team during the CNS Summit, please contact HMNCBrain@kcsa.com.

About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company headquartered in Munich, Germany, pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to higher remission rates. The company develops a unique pipeline targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). With a presence in both Germany and the U.S., HMNC is backed by renowned global venture capital firms, family offices, and strategic healthcare investors. For more information, visit www.hmnc-brainhealth.com.

About CNS Summit
CNS Summit is a multi-therapeutic, executive community of life sciences innovators and industry leaders devoted to discovering better, more efficient ways to develop new treatments for patients. Developed by the life sciences industry, for the life sciences industry, CNS Summit is a year-round, worldwide community that convenes each November in Boston for four days.

Media Contact (U.S.):
Anne Donohoe
(732) 620-0033
hmncbrain@kcsa.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.